Spruce Biosciences, Inc. – NASDAQ:SPRB
Spruce Biosciences stock price today
$8.95
+8.51
+1945.71%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Spruce Biosciences stock price monthly change
-23.81%
month
Spruce Biosciences stock price quarterly change
-23.81%
quarter
Spruce Biosciences stock price yearly change
-83.84%
year
Spruce Biosciences key metrics
Market Cap | 15.76M |
Enterprise value | 24.86M |
P/E | -1.01 |
EV/Sales | N/A |
EV/EBITDA | -0.35 |
Price/Sales | N/A |
Price/Book | 0.67 |
PEG ratio | 0.12 |
EPS | -1.14 |
Revenue | 10.12M |
EBITDA | -50.12M |
Income | -46.75M |
Revenue Q/Q | 1.93% |
Revenue Y/Y | 415.63% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -494.92% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSpruce Biosciences stock price history
Spruce Biosciences stock forecast
Spruce Biosciences financial statements
| Jun 2023 | 2.16M | -12.82M | -592.33% |
|---|---|---|---|
| Sep 2023 | 3.07M | -12.35M | -402.02% |
| Dec 2023 | 2.88M | -9.95M | -344.65% |
| Mar 2024 | 2.00M | -11.62M | -580.67% |
| Dec 2023 | 2.88M | -9.95M | -344.65% |
|---|---|---|---|
| Mar 2024 | 2.00M | -11.62M | -580.67% |
| Oct 2025 | 650K | -9.24M | -1422.56% |
| Dec 2025 | 650K | -11.71M | -1801.91% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.34 | -0.3 |
|---|---|---|
| 2024-03-13 | -0.41 | -0.23 |
| Jun 2023 | 125962000 | 29.40M | 23.34% |
|---|---|---|---|
| Sep 2023 | 112985000 | 27.60M | 24.43% |
| Dec 2023 | 103946000 | 27.43M | 26.4% |
| Mar 2024 | 87539000 | 20.91M | 23.89% |
| Jun 2023 | 1.99M | 22M | -432K |
|---|---|---|---|
| Sep 2023 | -12.26M | 13.99M | -405K |
| Dec 2023 | -11.20M | 9.3M | -552K |
| Mar 2024 | -14.95M | 0 | -227K |
Spruce Biosciences alternative data
| Aug 2023 | 30 |
|---|---|
| Sep 2023 | 32 |
| Oct 2023 | 32 |
| Nov 2023 | 32 |
| Dec 2023 | 31 |
| Jan 2024 | 31 |
| Feb 2024 | 31 |
| Apr 2024 | 29 |
| May 2024 | 29 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Spruce Biosciences other data
41.37%
-36.05%
of SPRB is owned by hedge funds
9.73M
-8.50M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 4172336 |
| Patent |
|---|
Application Filling date: 8 Feb 2022 Issue date: 7 Jul 2022 |
Grant Filling date: 25 Jun 2021 Issue date: 7 Jun 2022 |
Grant Filling date: 5 Oct 2020 Issue date: 31 May 2022 |
Application Filling date: 27 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 18 Jan 2022 Issue date: 5 May 2022 |
Grant Filling date: 25 Jun 2021 Issue date: 26 Apr 2022 |
Grant Filling date: 27 Oct 2020 Issue date: 19 Apr 2022 |
Application Filling date: 14 Aug 2018 Issue date: 25 Nov 2021 |
Application Filling date: 25 Jun 2021 Issue date: 21 Oct 2021 |
Application Filling date: 25 Jun 2021 Issue date: 21 Oct 2021 |
| Insider | Compensation |
|---|---|
Mr. Richard A. King M.B.A. (1964) Strategic Advisor | $839,550 |
Dr. Rosh Dias (1968) Chief Medical Officer | $623,440 |
Mr. Samir M. Gharib CPA, M.B.A., CPA (1982) Chief Financial Officer | $454,900 |
| Mr. Michael G. Grey (1953) Interim Chief Executive Officer & Executive Chairman | $14,850 |
-
What's the price of Spruce Biosciences stock today?
One share of Spruce Biosciences stock can currently be purchased for approximately $8.95.
-
When is Spruce Biosciences's next earnings date?
Unfortunately, Spruce Biosciences's (SPRB) next earnings date is currently unknown.
-
Does Spruce Biosciences pay dividends?
No, Spruce Biosciences does not pay dividends.
-
How much money does Spruce Biosciences make?
Spruce Biosciences has a market capitalization of 15.76M. Spruce Biosciences made a loss 47.92M US dollars in net income (profit) last year or -$0.23 on an earnings per share basis.
-
What is Spruce Biosciences's stock symbol?
Spruce Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "SPRB".
-
What is Spruce Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Spruce Biosciences?
Shares of Spruce Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Spruce Biosciences's key executives?
Spruce Biosciences's management team includes the following people:
- Mr. Richard A. King M.B.A. Strategic Advisor(age: 61, pay: $839,550)
- Dr. Rosh Dias Chief Medical Officer(age: 57, pay: $623,440)
- Mr. Samir M. Gharib CPA, M.B.A., CPA Chief Financial Officer(age: 43, pay: $454,900)
- Mr. Michael G. Grey Interim Chief Executive Officer & Executive Chairman(age: 72, pay: $14,850)
-
How many employees does Spruce Biosciences have?
As Jul 2024, Spruce Biosciences employs 22 workers, which is 24% less then previous quarter.
-
When Spruce Biosciences went public?
Spruce Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 9 Oct 2020.
-
What is Spruce Biosciences's official website?
The official website for Spruce Biosciences is sprucebiosciences.com.
-
Where are Spruce Biosciences's headquarters?
Spruce Biosciences is headquartered at 2001 Junipero Serra Boulevard, Daly City, CA.
-
How can i contact Spruce Biosciences?
Spruce Biosciences's mailing address is 2001 Junipero Serra Boulevard, Daly City, CA and company can be reached via phone at +41 56554168.
Spruce Biosciences company profile:
Spruce Biosciences, Inc.
sprucebiosciences.comExchange:
NASDAQ
Full time employees:
29
Industry:
Biotechnology
Sector:
Healthcare
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
2001 Junipero Serra Boulevard
Daly City, CA 94014
Daly City, CA 94014
CIK: 0001683553
ISIN: US85209E1091
CUSIP: 85209E109
